News & Updates

Show Multimedia Only

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

28 Nov 2025

Discontinuing treatment with GLP-1RAs before or early into pregnancy in women with obesity may lead to more gestational weight gain and increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy, according to a retrospective study.

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

28 Nov 2025

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

28 Nov 2025 by

Regular monitoring and recognizing tell-tale signs upon first presentation are important in managing endocrine immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs), for optimized cancer treatment outcomes, stressed Dr David Lui from the University of Hong Kong, at the 8^th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2025).

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

28 Nov 2025

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

27 Nov 2025 by

The PCSK9 inhibitor evolocumab, when added to background lipid-lowering therapy, helps reduce the risk of major adverse cardiovascular events in patients with atherosclerosis or diabetes who have no history of myocardial infarction (MI) or stroke, according to the randomized VESALIUS-CV trial.

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

27 Nov 2025

Dietary diversity tied to lower risk of metabolic syndrome

27 Nov 2025

A diverse diet seems to reduce the risk of metabolic syndrome, suggests a Japan study.

Dietary diversity tied to lower risk of metabolic syndrome

27 Nov 2025

Primary hyperparathyroidism linked to cardiometabolic risks

27 Nov 2025

Individuals with primary hyperparathyroidism (pHPT) face long-term cardiometabolic risks, as reported in a retrospective study.

Primary hyperparathyroidism linked to cardiometabolic risks

27 Nov 2025

Tirzepatide trims risk of major adverse cardiovascular events

26 Nov 2025 by

Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.

Tirzepatide trims risk of major adverse cardiovascular events

26 Nov 2025

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD

25 Nov 2025 by

The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD

25 Nov 2025

Semaglutide lowers kidney fat, improves glomerular haemodynamic in T2D patients with CKD

25 Nov 2025 by

Treatment with semaglutide helps reduce kidney fat and enhance glomerular haemodynamic in adult patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the REMODEL trial.

Semaglutide lowers kidney fat, improves glomerular haemodynamic in T2D patients with CKD

25 Nov 2025

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

22 Nov 2025

Treatment with immune checkpoint inhibitors (ICI) is safe and feasible in patients with aggressive pituitary neuroendocrine tumours (PNTs), a recent study has shown.

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

22 Nov 2025

SGLT2 inhibitors help prevent anaemia in patients with diabetes

21 Nov 2025

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors resulted in a reduced prevalence of anaemia and decreased risk of hospitalizations due to anaemia relative to the use of dipeptidyl peptidase 4 (DPP4) inhibitors in patients with diabetes, reports a study.

SGLT2 inhibitors help prevent anaemia in patients with diabetes

21 Nov 2025

News & Updates

Filter by Specialty:

Specialty:

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

Dietary diversity tied to lower risk of metabolic syndrome

Dietary diversity tied to lower risk of metabolic syndrome

Primary hyperparathyroidism linked to cardiometabolic risks

Primary hyperparathyroidism linked to cardiometabolic risks

Tirzepatide trims risk of major adverse cardiovascular events

Tirzepatide trims risk of major adverse cardiovascular events

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD

Semaglutide lowers kidney fat, improves glomerular haemodynamic in T2D patients with CKD

Semaglutide lowers kidney fat, improves glomerular haemodynamic in T2D patients with CKD

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

SGLT2 inhibitors help prevent anaemia in patients with diabetes

SGLT2 inhibitors help prevent anaemia in patients with diabetes